Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Femara Generic Name & Formulations
Legal Class
Rx
General Description
Letrozole 2.5mg; tabs.
Pharmacological Class
Aromatase inhibitor.
How Supplied
Tabs—30
Manufacturer
Femara Indications
Indications
In postmenopausal women: Adjuvant treatment of hormone receptor positive early breast cancer; Extended adjuvant treatment of early breast cancer after 5 years of adjuvant tamoxifen therapy; First-line treatment of hormone receptor positive or unknown, locally advanced or metastatic breast cancer; Treatment of advanced breast cancer with disease progression following antiestrogen therapy.
Femara Dosage and Administration
Adult
2.5mg once daily. Adjuvant or extended adjuvant therapy: discontinue at tumor relapse; see full labeling. Advanced breast cancer: continue until tumor progression is evident. Severe hepatic impairment or cirrhosis: 2.5mg every other day.
Children
Not established.
Femara Contraindications
Contraindications
Pregnancy.
Femara Boxed Warnings
Not Applicable
Femara Warnings/Precautions
Warnings/Precautions
Monitor bone mineral density, serum cholesterol. Severe renal or hepatic impairment. Embryo-fetal toxicity; exclude pregnancy prior to initiation. Use effective contraception during and for ≥3wks after last dose. Nursing mothers: not recommended (during and for ≥3wks after last dose).
Femara Pharmacokinetics
See Literature
Femara Interactions
Not Applicable
Femara Adverse Reactions
Adverse Reactions
Pain (bone, musculoskeletal, and others), hot flashes, arthralgia, flushing, asthenia, edema, headache, dizziness, hypercholesterolemia, sweating increased, GI upset, fatigue, somnolence, dyspnea, cough, insomnia, hypertension, anorexia, weight changes; thromboembolic or cardio- or cerebrovascular events (rare).
Femara Clinical Trials
See Literature
Femara Note
Not Applicable
Femara Patient Counseling
See Literature
Images
